WALTHAM, Mass. , Jan. 17, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq:NURO) announced today a collaboration with GlaxoSmithKline (NYSE:GSK), one of the world's largest science-led global healthcare companies, involving Quell ® Wearable Pain Relief Technology™.
WALTHAM, Mass. , Jan. 18, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (NASDAQ:NURO) announced today that it plans to issue its fourth quarter and full year 2017 financial results before the opening of the market on January 25, 2018. The Company will host a conference call at 8:00 a.m., Eastern
Q4 revenue $4.9M up 33%. Full year 2017 revenue $17.1M up 42%. WALTHAM, Mass. , Jan. 25, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), today reported financial and business highlights for the quarter ended December 31, 2017 . The Company develops and markets novel therapies, based on
WALTHAM, Mass. , March 01, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq:NURO) today reported that it will present a scientific poster at the upcoming 2018 American Pain Society (APS) Annual Scientific Meeting to be held in Anaheim, CA, March 4-6.
WALTHAM, Mass. , April 10, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), today reported publication of results from a clinical study of Quell® in the Journal of Pain Research . The paper is titled “Effectiveness of fixed-site high-frequency transcutaneous electrical nerve stimulation
WALTHAM, Mass. , April 11, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq:NURO) announced today that it plans to issue its 2018 first quarter financial results before the opening of the market on Thursday, April 19, 2018. The Company will host a conference call at 8:00 a.m., Eastern
WALTHAM, Mass. , April 18, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) today reported that it will present a scientific poster at the upcoming 2018 American Academy of Neurology (AAN) Annual Meeting to be held in Los Angeles, CA , April 21-27 .
GlaxoSmithKline Collaboration is Quarter Highlight WALTHAM, Mass. , April 19, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), today reported financial and business highlights for the quarter ended March 31, 2018 . The Company develops and markets novel therapies, based on neurostimulation
GlaxoSmithKline Collaboration is Quarter Highlight WALTHAM, Mass. , April 19, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), today reported financial and business highlights for the quarter ended March 31, 2018 . The Company develops and markets novel therapies, based on neurostimulation
WALTHAM, Mass. , April 24, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) today reported that it will present two scientific posters at the upcoming 2018 American Academy of Pain Medicine (AAPM) Annual Meeting to be held in Vancouver, Canada , April 26-28 .
